Stryker Corporation (SYK) Financial Statements

Stryker Corporation

SYK · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$25.12B	$22.59B	$20.50B	$18.45B	$17.11B	$14.35B	$14.88B	$13.60B
Cost of Revenue	$9.05B	$8.15B	$7.44B	$6.87B	$6.14B	$5.29B	$5.19B	$4.66B
Gross Profit	$16.07B	$14.44B	$13.06B	$11.58B	$10.97B	$9.06B	$9.70B	$8.94B
Research & Development	$1.62B	$1.47B	$1.39B	$1.45B	$1.24B	$984.00M	$971.00M	$862.00M
Selling, General & Administrative	$8.65B	$7.68B	$7.11B	$6.39B	$6.43B	$5.36B	$5.36B	$5.10B
Operating Expenses	$11.18B	$10.75B	$9.17B	$8.74B	$8.38B	$6.83B	$6.98B	$6.40B
Operating Income	$4.89B	$3.69B	$3.89B	$2.84B	$2.58B	$2.22B	$2.71B	$2.54B
Interest Expense	$582.00M	$396.00M	$356.00M	$337.00M	$337.00M	$315.00M	$287.00M	$264.00M
Other Income / (Expense)	$232.00M	$212.00M	$148.00M	-$158.00M	-$303.00M	-$269.00M	-$151.00M	-$181.00M
Income Before Taxes	$4.51B	$3.49B	$3.67B	$2.68B	$2.28B	$1.95B	$2.56B	$2.36B
Provision for Income Taxes	$1.27B	$499.00M	$508.00M	$325.00M	$287.00M	$355.00M	$479.00M	-$1.20B
Net Income	$3.25B	$2.99B	$3.17B	$2.36B	$1.99B	$1.60B	$2.08B	$3.55B
Basic EPS	$8.49	$7.86	$8.34	$6.23	$5.29	$4.26	$5.57	$9.50
Diluted EPS	$8.40	$7.76	$8.25	$6.17	$5.21	$4.20	$5.48	$9.34
Basic Shares Outstanding	382.20M	381.00M	379.60M	378.20M	377.00M	375.50M	374.00M	374.10M
Diluted Shares Outstanding	386.50M	385.60M	383.70M	382.20M	382.30M	380.30M	379.90M	380.30M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$15.02	$14.95	$15.05	10	↑7 ↓2
Dec 2027	$16.75	$16.46	$17.08	11	↑8 ↓1
Dec 2028	$18.46	$17.56	$18.80	5	↑3 ↓1
Dec 2029	$19.95	$19.22	$20.69	2	↑2 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: SYK
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Key Issues

Bullish view

The second quarter showed 9% organic sales growth and 17.9% adjusted EPS growth, indicating that sales momentum is returning after the cybersecurity disruption and can support renewed operating leverage.

Bearish view

Management narrowed 2026 guidance despite the earnings beat, suggesting that the recovery may be less complete or less predictable than the headline results imply.

Analyst Consensus

See all

Buy

24 analysts

$335

Current

$340

Low

$378

Average

$400

High

Average target implies +12.79% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Bristol-Myers Squibb Company